Scarletred acquires high potential phase II skin drug project SOD

Scarletred acquires all rights and therewith connected international patents on already clinical phase II developed recombinant human Superoxide Dismutase (SOD) from its former developer APEIRON Biologics AG.

It further contracts POLYMUN Scientific Immunbiologische Forschung GmbH for exclusive manufacturing of the SkinDrug and opens now for investor and partnering activities.
Mode of action: SOD is nature’s most efficient anti-oxidative enzyme acting by neutralizing harmful superoxide anion radicals. The biologics harbors high therapeutic and cosmeceutical potential based on its anti-inflammatory, anti-edematous and clinically proven pain-relieving effects.

CEO, Schnidar: Our recent acquisition of a phase II skin drug project, is unique for a startup in Austria and I am absolutely sure this happens also only rarely internationally, underlining the broad expertise of our team and high intrinsic potential of the company. We think big and are now aiming on to attract substantial private equity to further clinically develop our product pipeline and to commercialize our innovative dermatologic products globally.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)